MedTrace Logo

A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy

NCT01242917 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2025-03-06

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.

Conditions

Interventions

DRUG

CCX-354-C

200mg film-coated tablets once daily for 12 weeks + Methotrexate

DRUG

Placebo

Placebo film-coated tablets twice daily for 12 weeks + methotrexate

DRUG

CCX354-C

100mg film-coated tablets twice daily for 12 weeks + methotrexate

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Belgium
  • Czechia
  • Germany
  • Hungary
  • Netherlands
  • Poland
  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242917 on ClinicalTrials.gov